Neuroleptic malignant syndrome.
Mueller
P S
PS
D000328:Adult; D000978:Antiparkinson Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000503:physiopathology*; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D011954:Receptors, Dopamine / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000209:etiology
D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D011954:Receptors, Dopamine; D001971:Bromocriptine